We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+69.49%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$617M
AUM Growth
–
Cap. Flow
+$516M
Cap. Flow %
83.64%
Top 10 Hldgs %
46.54%
Holding
114
New
114
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$16.4M
2
CHMA
Chiasma, Inc. Common Stock
CHMA
+$5.74M
3
IMVT icon
Immunovant
IMVT
+$5.65M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.43M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.34M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 16.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$7.36M 1.19%
+240,300
New +$6.65M
INCY icon
27
CALL
Incyte
INCY
$24.9B
$6.99M 1.13%
+80,000
New +$6.83M
ARQL
28
PUT
DELISTED
Arqule Inc
ARQL
$6.71M 1.09%
+336,400
New +$3.9M
ARWR icon
29
CALL
Arrowhead Research
ARWR
$11.8B
$6.34M 1.03%
+100,000
New +$4.96M
ARWR icon
30
PUT
Arrowhead Research
ARWR
$11.8B
$6.34M 1.03%
+100,000
New +$4.96M
MRTX
31
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.3M 1.02%
+48,900
New +$4.72M
DCPH
32
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.22M 1.01%
+100,000
New +$4.75M
ACAD icon
33
PUT
Acadia Pharmaceuticals
ACAD
$4.39B
$5.99M 0.97%
+140,000
New +$6.09M
EIDX
34
CALL
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$5.74M 0.93%
+100,000
New +$4.95M
APTO
35
DELISTED
Aptose Biosciences, Inc.
APTO
$5.72M 0.93%
+2,244
New +$2.92M
CHMA
36
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.47M 0.89%
+1,103,297
New +$5.74M
CLVS
37
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$5.36M 0.87%
+513,700
New +$3.74M
ARDX icon
38
Ardelyx
ARDX
$1.25B
$4.84M 0.78%
+645,436
New +$3.92M
AMRN
39
CALL
Amarin Corp
AMRN
$290M
$4.66M 0.76%
+10,875
New +$4.13M
ADVM
40
CALL
DELISTED
Adverum Biotechnologies
ADVM
$4.5M 0.73%
+39,090
New +$3.45M
MYOK
41
PUT
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.3M 0.7%
+59,000
New +$3.58M
OTIC
42
DELISTED
Otonomy, Inc.
OTIC
$4.09M 0.66%
+1,067,271
New +$2.61M
MDGL icon
43
Madrigal Pharmaceuticals
MDGL
$12.4B
$4.08M 0.66%
+44,770
New +$4.34M
KPTI icon
44
PUT
Karyopharm Therapeutics
KPTI
$155M
$3.84M 0.62%
+13,340
New +$2.89M
KALV
45
DELISTED
KalVista Pharmaceuticals
KALV
$3.78M 0.61%
+212,420
New +$2.77M
KALA icon
46
KALA BIO
KALA
$12.1M
$3.78M 0.61%
+410
New +$3.96M
TGTX icon
47
TG Therapeutics
TGTX
$8.5B
$3.51M 0.57%
+316,200
New +$2.4M
ASMB icon
48
Assembly Biosciences
ASMB
$500M
$3.22M 0.52%
+13,122
New +$2.42M
XENE icon
49
Xenon Pharmaceuticals
XENE
$6.28B
$3.19M 0.52%
+243,470
New +$2.56M
ANAB icon
50
PUT
AnaptysBio
ANAB
$1.57B
$3.14M 0.51%
+193,300
New +$4.57M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Ikarian Capital, which disclosed 114 positions worth $617M. Its ten largest holdings account for 47% of the portfolio.

Its largest position is Sage Therapeutics: 133,000 shares worth $9.6M.

By sector, the portfolio is most concentrated in Healthcare at 16% of assets.

  • Ikarian Capital's largest Q4 2019 buy was Sage Therapeutics: 133,000 shares worth $9.6M.
  • Ikarian Capital's ten largest holdings make up 47% of its $617M portfolio in Q4 2019.
  • Ikarian Capital disclosed 114 positions in Q4 2019, its first 13F filing on record.

Based on Ikarian Capital's 13F filing for Q4 2019, filed 31 Jan 2020.